DexCom (DXCM) — Company Research
Last Updated: 21 June 2026
DexCom is a pure-play leader in continuous glucose monitoring (CGM), the wearable biosensor technology that has transformed diabetes care and is now expanding into the much larger market of people not on insulin. The company pairs strong double-digit revenue growth with rapidly improving profitability, and in 2025 it crossed $4.6bn of revenue while launching its 15-day G7 sensor and previewing a next-generation G8 platform. This report examines DexCom's financials, valuation, competitive position and risks using only primary-source filings and company press releases. For live pricing see our Live Charts, scheduled catalysts on the Economic Calendar, and discussion in the Forum.
1. Company Snapshot
| Field | Value |
|---|---|
| Company | DexCom, Inc. |
| Ticker / Exchange | DXCM (Nasdaq) |
| Sector | Healthcare — Medical Devices |
| Market cap | ~$28bn (June 2026) |
| Share price | ~$72 (19 June 2026) |
| Revenue (FY2025) | $4.66bn |
| Net income (FY2025) | $836m |
| GAAP EPS (FY2025) | $2.09 |
| Non-GAAP EPS (FY2025) | $2.09 |
| Dividend | None — DexCom pays no dividend |
| Employees | ~10,000+ (global) |
| CEO | Jake Leach (President & CEO since 1 January 2026) |
| Headquarters | San Diego, California, USA |
| Next earnings | Q2 2026 — expected late July 2026 |
2. Bull & Bear Case
Bull Case
- Durable double-digit growth: revenue grew 16% to $4.662bn in 2025 and management guides 11–13% growth in 2026 ($5.16–$5.25bn), underpinned by a large, expanding diabetes and pre-diabetes population.
- Margins inflecting upward: GAAP operating margin rose to 19.6% in 2025 from ~15%, with Q1 2026 hitting 21.4%; non-GAAP operating margin is guided to 23–23.5% for 2026.
- Product cadence and TAM expansion: the G7 15-day sensor, the over-the-counter Stelo platform for non-insulin users, and the previewed G8 widen both accuracy leadership and addressable market.
- Strong balance sheet: ~$2.4bn of cash and marketable securities against ~$1.24bn of convertible notes gives net cash and ample capacity to fund manufacturing expansion.
- Highly cash-generative: FY2025 free cash flow of roughly $1bn supports continued reinvestment without external financing.
Bear Case
- Formidable competition from Abbott: Abbott's FreeStyle Libre franchise is larger by revenue (~$5.3bn in 2024) and competes hard on price and extended wear, pressuring share and pricing.
- Premium valuation: a ~34x trailing GAAP P/E and high-20s price-to-free-cash-flow leave little margin for error if growth decelerates.
- Reimbursement and pricing risk: CGM economics depend on payer coverage and pharmacy channel pricing, which can compress as volumes scale and competition intensifies.
- One-off boost to 2025 earnings: FY2025 GAAP net income was flattered by a ~$78m gain on equity investments, overstating the underlying earnings run-rate.
- New leadership and crowded field: a CEO transition (Jake Leach from 1 January 2026) coincides with new entrants (Senseonics implantables, Biolinq microneedles, Medtronic interoperability) crowding the CGM space.
3. Business Segments
DexCom operates as a single reportable segment (continuous glucose monitoring). The table below disaggregates FY2025 revenue by geography, which is how the company reports its sales mix.
| Segment | % of revenue | What it is |
|---|---|---|
| United States | ~72% | Sales of Dexcom CGM (G7/G6, Stelo OTC) in the US, predominantly through distributors and the pharmacy channel. FY2025 revenue $3.33bn. |
| International | ~28% | CGM sales outside the US across Europe, Asia-Pacific and other regions, via both direct and distributor channels. FY2025 revenue $1.33bn. |
By channel, distributors accounted for roughly $3.96bn (about 85%) of FY2025 revenue and direct sales for about $0.70bn (about 15%).
4. Business Model
DexCom sells wearable glucose biosensors and the software that turns their data into actionable insight. The model is a razor-and-blade variant: customers adopt the system, then buy disposable sensors on a recurring basis.
How it makes money: the overwhelming majority of revenue is recurring sensor sales. A sensor is worn for up to 10–15 days and then replaced, so an installed base of users generates predictable, repeat demand. Revenue flows mainly through distributors and pharmacies, with a growing direct channel for the OTC Stelo product.
Unit economics: gross margins are high (GAAP gross margin ~62.9% in Q1 2026) and improve with manufacturing scale and automation in Arizona, Ireland and Malaysia. Because demand is recurring, customer lifetime value is large relative to acquisition cost once a patient is on the platform and reimbursed.
Moat and strategy: the moat is accuracy, clinical evidence, regulatory clearances, payer coverage and integration with insulin pumps (Tandem, Insulet, Beta Bionics). Strategy is to defend accuracy leadership with G7 15-day and G8, while expanding the addressable market into the far larger non-insulin and wellness population through Stelo.
5. Financial Health
DexCom combines rapid revenue growth with a recent step-change in profitability. The five-year record below reflects the four-for-one stock split effected in June 2022 (all per-share figures are split-adjusted). FY2025 GAAP and non-GAAP diluted EPS both landed at $2.09, with GAAP including a one-off equity-investment gain. Figures are from DexCom's annual and quarterly earnings press releases.
| Fiscal Year | Revenue ($bn) | YoY % | GAAP EPS | Adjusted EPS | Dividend/share | Long-term debt (YE, $m) |
|---|---|---|---|---|---|---|
| FY2021 | 2.45 | — | $0.53 | — | None | — |
| FY2022 | 2.91 | +18.8% | $0.82 | — | None | — |
| FY2023 | 3.62 | +24.5% | $1.30 | — | None | — |
| FY2024 | 4.03 | +11.4% | $1.42 | $1.64 | None | 1,237 |
| FY2025 | 4.66 | +15.6% | $2.09 | $2.09 | None | 1,241 |
The most recent five quarters show steady mid-teens revenue growth and sharply higher margins. Q3 2025 GAAP EPS of $0.70 exceeded non-GAAP EPS because it included the ~$78m equity-investment gain.
| Quarter | Revenue ($m) | Adjusted EPS | GAAP EPS |
|---|---|---|---|
| Q1 2026 | 1,191.9 | $0.56 | $0.51 |
| Q4 2025 | 1,259.6 | $0.68 | $0.68 |
| Q3 2025 | 1,209.0 | $0.61 | $0.70 |
| Q2 2025 | 1,157.0 | $0.48 | $0.45 |
| Q1 2025 | 1,036.0 | $0.32 | $0.27 |
| FY2025 total | 4,662.0 | $2.09 | $2.09 |
6. Valuation
Raw metrics, June 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Market cap | ~$28bn (June 2026) |
| Enterprise value | ~$26.6bn (market cap ~$28bn + total debt ~$1.24bn − cash & marketable securities ~$2.42bn, per 31 Mar 2026 balance sheet) |
| Trailing P/E (GAAP) | ~34x (price ~$72 / FY2025 GAAP EPS $2.09; note FY2025 EPS includes a ~$78m one-off equity-investment gain) |
| P/E (forward) | n/a — DexCom does not issue EPS guidance |
| P/S (TTM) | ~5.8x (market cap ~$28bn / TTM revenue ~$4.82bn) |
| EV/EBITDA (TTM) | ~23x (EV ~$26.6bn / FY2025 EBITDA ~$1.16bn; EBITDA = operating income $911.8m + D&A $251.8m; on adjusted EBITDA of $1.35bn, ~20x) |
| P/FCF | ~27x (market cap ~$28bn / FY2025 free cash flow ~$1.04bn; FCF = operating CF ~$1.4bn − capex ~$0.36bn) |
| 52-week high | $89.98 |
| 52-week low | $54.11 |
| Short interest (% of float) | ~2.6% (≈9.1m shares, 2026) |
| Days to cover | ~1 day (approx., on recent average volume) |
7. What Are They Building
DexCom is pushing on hardware and software simultaneously. On hardware, the headline 2026 development is the G7 15-day sensor, which extends wear time with a new algorithm, better accuracy and smoother data, and connects to Insulet and Beta Bionics pumps (with Tandem to follow). At its 2026 Investor Day the company unveiled the next-generation Dexcom G8, described as roughly half the size of the G7, with a 15-day standard wear and a sensor that self-calibrates to the user over its life.
On software and market expansion, the over-the-counter Stelo platform targets the large population of people not on insulin; a redesigned, FDA-cleared Stelo app launched in 2026 with pattern recognition, AI coaching and personalised summaries. The company also continues to build clinical evidence, presenting CONNECT randomised-trial results at the ADA 2026 Scientific Sessions in June and one-year registry data showing A1C improvement in non-insulin type 2 diabetes. Capacity expansion in Ireland and Malaysia underpins the volume ramp.
8. Competitive Landscape
DexCom competes primarily with Abbott in CGM, alongside Medtronic in integrated insulin-pump systems and a growing set of niche entrants.
| Peer | Market cap (June 2026) | Key 2025 metric |
|---|---|---|
| Abbott Laboratories (ABT) | ~$230bn | FreeStyle Libre CGM franchise ~$5.3bn revenue (2024), the largest in CGM |
| Medtronic (MDT) | ~$115bn | ~12% integrated insulin-pump share; MiniMed 780G cleared for type 2 use in 2025 |
| Senseonics (SENS) | ~$0.6bn | Eversense 365 implantable CGM; Q1 2026 revenue $11.7m, up 87% YoY |
Abbott is the principal rival by scale; DexCom differentiates on accuracy, pump integrations and clinical evidence. The broader CGM market was valued at roughly $13bn in 2025 and is projected to grow at a mid-teens CAGR, leaving room for multiple players. Peer market caps are approximate as of June 2026.
9. Leadership & Ownership
Jake Leach became President and Chief Executive Officer on 1 January 2026, having previously served as chief operating officer; long-time CEO Kevin Sayer moved to an executive chair role. The leadership team is deep in CGM technology and commercial execution. No material insider open-market transactions beyond routine equity compensation and scheduled Rule 10b5-1 activity were identified in recent Form 4 filings during this review.
DexCom is broadly institutionally owned, typical of a US large-cap medical-device company, with index funds and growth managers among the largest holders. The absence of a dividend means total shareholder return depends on share-price appreciation and the company's continued reinvestment in growth.
10. Risks
- Competition (Operational): Abbott's larger Libre franchise and new entrants (Senseonics, Biolinq, Medtronic interoperability) could erode share and pricing.
- Valuation (Financial): a premium multiple means any growth or margin disappointment could trigger an outsized share-price reaction.
- Reimbursement (Regulatory): changes to payer coverage, pharmacy pricing or government reimbursement policy could compress revenue and margins.
- Regulatory & clinical (Regulatory): new products such as G8 and Stesto features depend on timely FDA clearances; delays or label limitations would slow growth.
- Concentration (Operational): revenue is concentrated in CGM and flows heavily through a small number of large distributors, creating channel and product-concentration risk.
- Manufacturing & supply (Operational): rapid capacity expansion in multiple countries carries execution, quality and supply-chain risk that could affect availability or cost.
11. Recent Developments
- 30 Apr 2026 — Q1 2026 results. Revenue grew 15% to $1.192bn, GAAP operating margin reached 21.4%, GAAP EPS $0.51 and non-GAAP EPS $0.56; full-year operating-margin and adjusted-EBITDA-margin guidance were raised.
- 12 Feb 2026 — FY2025 results. Full-year revenue grew 16% to $4.662bn with GAAP operating income of $911.8m (19.6% margin) and GAAP EPS of $2.09.
- 06 Jun 2026 — CONNECT trial at ADA 2026. DexCom presented randomised controlled trial data at the American Diabetes Association Scientific Sessions supporting CGM benefits.
- 01 Jan 2026 — CEO transition. Jake Leach became President and CEO, with Kevin Sayer moving to executive chair.
12. Key Dates
- Expected 30 Jul 2026 — Q2 2026 earnings release (date to be confirmed)
- Expected H2 2026 — continued G7 15-day rollout and Dexcom G8 development milestones
- Expected Feb 2027 — Q4 and full-year 2026 results
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Loading research report…
13. Thesis Verdict
The central thesis. DexCom is a pure-play leader in continuous glucose monitoring, earning recurring revenue from disposable biosensors worn by people with diabetes and, increasingly, non-insulin users via its Stelo platform. In FY2025 revenue grew 16% to $4.66bn with GAAP operating income of $911.8m (19.6% margin) and GAAP EPS of $2.09; management guides 11–13% revenue growth and further margin expansion in 2026. The key drivers are the G7 15-day sensor, the previewed G8, and expansion of the addressable market beyond insulin users.
What would confirm or break it. Sustained mid-teens revenue growth, margin expansion and successful product launches would confirm the bull case. The thesis would weaken if Abbott's larger Libre franchise erodes share or pricing, if reimbursement and pharmacy pricing compress margins, or if the premium valuation de-rates on any growth disappointment.
Watchpoints
- ConfirmsQ2 2026 earnings (39 days) landing in line with or above management guidance.
- ConfirmsEvidence supporting the "Durable double-digit growth:" thesis continuing to build across subsequent filings.
- InvalidatesMaterialisation of the "Competition (Operational):" risk, or any disclosure that fundamentally alters the capital-return or growth profile stated by management.
Diagnostic grid
Generated by ChartsView research tooling. Thesis strength measures how well the evidence in this report supports the company's stated thesis — it is NOT a buy/sell rating or price target. ChartsView is not authorised by the FCA to provide regulated investment advice. Generated 21 Jun 2026.